Literature DB >> 7416906

Serum haloperidol determinations in psychiatric patients. Comparison of methods and correlation with serum prolactin level.

R T Rubin, A Forsman, J Heykants, R Ohman, B Tower, M Michiels.   

Abstract

Twenty-one serum samples from 11 schizophrenic patients receiving long-term haloperidol therapy were analyzed for haloperidol concentrations by two different radioimmunoassays (RIAs) and gas chromatography (GC). There was a good correspondence between the RIA and GC values over a wide range of drug concentrations. However, compared with the specific GC technique, both RIA methods overestimated haloperidol concentrations, reflecting differences in the specificities of the two RIA antibodies. One of the RIA methods had the requisite specificity for application to patients treated with long-term haloperidol therapy, although further methodological refinement will be required for its general clinical application. Haloperidol values determined by GC and RIA analyses correlated highly with prolactin concentrations in the same samples, suggesting that the usefulness of prolactin measurement as an "in vivo bioassay" for circulating levels of haloperidol should be further explored.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7416906     DOI: 10.1001/archpsyc.1980.01780220107012

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  6 in total

1.  Serum and CSF levels of haloperidol by radioimmunoassay and radioreceptor assay during high-dose therapy of resistant schizophrenic patients.

Authors:  R Rimón; I Averbuch; P Rozick; L Fijman-Danilovich; T Kara; H Dasberg; R P Ebstein; R H Belmaker
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

Review 2.  The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia.

Authors:  S Ulrich; C Wurthmann; M Brosz; F P Meyer
Journal:  Clin Pharmacokinet       Date:  1998-03       Impact factor: 6.447

Review 3.  Plasma level monitoring of antipsychotic drugs. Clinical utility.

Authors:  S G Dahl
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

4.  On the distribution and elimination of haloperidol in cholecystectomized patients.

Authors:  A Forsman; M Larsson; H Lundborg; P Renstrom
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1981       Impact factor: 2.441

5.  Haloperidol plasma levels and clinical response in paranoid schizophrenics.

Authors:  P Linkowski; P Hubain; R von Frenckell; J Mendlewicz
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1984

Review 6.  Pharmacokinetics of haloperidol.

Authors:  J S Froemming; Y W Lam; M W Jann; C M Davis
Journal:  Clin Pharmacokinet       Date:  1989-12       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.